Old Web
English
Sign In
Acemap
>
authorDetail
>
Josh Yuan
Josh Yuan
Takeda Pharmaceutical Company
Chemistry
Pharmacology
Biochemistry
CD38
Monoclonal antibody
6
Papers
135
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A reduction in B, T, and NK cells expressing CD38 by TAK-079 inhibits the induction and progression of collagen-induced arthritis in cynomolgus monkeys
2019
Journal of Pharmacology and Experimental Therapeutics
Wouter Korver
Mary Carsillo
Josh Yuan
Neeraja Idamakanti
Matthew Wagoner
Pu Shi
Cindy Q. Xia
Glennda Smithson
Lachy McLean
Jonathan Zalevsky
E Fedyk
Show All
Source
Cite
Save
Citations (10)
A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the “Metabolites in Safety Testing” Regulatory Guidance
2018
Drug Metabolism and Disposition
Simone Schadt
Bojan Bister
Swapan Chowdhury
Christoph Funk
Cornelis E. C. A. Hop
W. Griffith Humphreys
Fumihiko Igarashi
Alexander-David James
Mark Kagan
S. Cyrus Khojasteh
Angus Nedderman
Chandra Prakash
Frank Runge
Holger Scheible
Douglas K. Spracklin
Piet Swart
Susanna Tse
Josh Yuan
R. Scott Obach
Show All
Source
Cite
Save
Citations (32)
TAK-079 is a high affinity monoclonal antibody that effectively mediates CD38+ cell depletion
2017
Journal of Immunology
Glennda Smithson
Jonathan Zalevsky
Wouter Korver
Stefan Roepcke
Martin Dahl
Lin Zhao
Josh Yuan
Lachy McLean
Kathleen Ann Elias
Show All
Source
Cite
Save
Citations (5)
Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice
2003
Drug Metabolism and Disposition
Ji Y. Zhang
Josh Yuan
Yuefen Wang
Roy H. Bible
Alan P. Breau
Show All
Source
Cite
Save
Citations (32)
Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human
2002
Drug Metabolism and Disposition
Josh Yuan
Dai Chang Yang
Ji Y. Zhang
Roy H. Bible
Aziz Karim
John W. A. Findlay
Show All
Source
Cite
Save
Citations (48)
1